Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies

NCT02650986 is registered in ClinicalTrials.gov with Roswell Park Cancer Institute as lead sponsor.

NCT NCT02650986
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02650986 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa Study of TGFß Blockade in TCR-Engineered T-Cell Cancer Immunotherapy in Patients With Advanced Malignancies
Lead sponsor
Roswell Park Cancer Institute
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
July 14, 2017
Completion date
July 14, 2032
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced fallopian tube carcinoma, advanced malignant solid neoplasm, advanced melanoma, advanced ovarian carcinoma, advanced primary peritoneal carcinoma, advanced synovial sarcoma, clinical stage iii cutaneous melanoma ajcc v8, clinical stage iv cutaneous melanoma ajcc v8, metastatic fallopian tube carcinoma, metastatic melanoma, metastatic ovarian carcinoma, metastatic primary peritoneal carcinoma, metastatic synovial sarcoma, pathologic stage iii cutaneous melanoma ajcc v8, pathologic stage iiia cutaneous melanoma ajcc v8, pathologic stage iiib cutaneous melanoma ajcc v8, pathologic stage iiic cutaneous melanoma ajcc v8, pathologic stage iiid cutaneous melanoma ajcc v8, pathologic stage iv cutaneous melanoma ajcc v8, platinum-resistant fallopian tube carcinoma, platinum-resistant ovarian carcinoma, platinum-resistant primary peritoneal carcinoma, stage iii fallopian tube cancer ajcc v8, stage iii ovarian cancer ajcc v8, stage iii primary peritoneal cancer ajcc v8, stage iiia fallopian tube cancer ajcc v8, stage iiia ovarian cancer ajcc v8, stage iiia primary peritoneal cancer ajcc v8, stage iiia1 fallopian tube cancer ajcc v8, stage iiia1 ovarian cancer ajcc v8, stage iiia2 fallopian tube cancer ajcc v8, stage iiia2 ovarian cancer ajcc v8, stage iiib fallopian tube cancer ajcc v8, stage iiib ovarian cancer ajcc v8, stage iiib primary peritoneal cancer ajcc v8, stage iiic fallopian tube cancer ajcc v8, stage iiic ovarian cancer ajcc v8, stage iiic primary peritoneal cancer ajcc v8, stage iv fallopian tube cancer ajcc v8, stage iv ovarian cancer ajcc v8, stage iv primary peritoneal cancer ajcc v8, stage iva fallopian tube cancer ajcc v8, stage iva ovarian cancer ajcc v8, stage iva primary peritoneal cancer ajcc v8, stage ivb fallopian tube cancer ajcc v8, stage ivb ovarian cancer ajcc v8, stage ivb primary peritoneal cancer ajcc v8, unresectable melanoma, unresectable ovarian carcinoma, unresectable synovial sarcoma